Pacer Advisors Inc. Purchases 26,044 Shares of Roivant Sciences Ltd. $ROIV

Pacer Advisors Inc. raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 37.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,303 shares of the company’s stock after acquiring an additional 26,044 shares during the quarter. Pacer Advisors Inc.’s holdings in Roivant Sciences were worth $2,668,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. SBI Securities Co. Ltd. lifted its stake in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP increased its position in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the last quarter. Parallel Advisors LLC increased its position in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after buying an additional 520 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in Roivant Sciences in the fourth quarter valued at approximately $47,000. Finally, Bessemer Group Inc. raised its stake in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after buying an additional 441 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 3.5%

Shares of NASDAQ:ROIV opened at $36.34 on Friday. Roivant Sciences Ltd. has a 12-month low of $10.90 and a 12-month high of $37.00. The business has a 50 day moving average of $33.13 and a 200-day moving average of $29.46. The stock has a market cap of $26.14 billion, a PE ratio of -68.57 and a beta of 1.12.

Trending Headlines about Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Guggenheim raised its price target to $42 from $36 and assigned a “Buy” rating. The revision implies meaningful upside and provides a clear near-term bullish catalyst for Roivant Sciences (ROIV). Benzinga analyst upgrade
• Positive Sentiment: Roivant said it expects to launch brepocitinib for dermatomyositis by the end of September, a milestone that could improve confidence in the company’s commercialization strategy. It also plans to target cutaneous sarcoidosis, with Phase 3 data expected in 2028. Brepocitinib launch and pipeline update
• Positive Sentiment: Roivant’s subsidiary Immunovant reported that IMVT-1402 development remains on schedule across several autoimmune indications, including Graves’ disease and myasthenia gravis. Its cash balance is expected to fund operations through a potential Graves’ disease launch, reducing near-term financing concerns. Immunovant corporate update

Insider Buying and Selling

In other Roivant Sciences news, Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total value of $436,766.40. Following the transaction, the director directly owned 13,689,166 shares of the company’s stock, valued at $482,953,776.48. This represents a 0.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Melissa B. Epperly sold 17,750 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,055,913 shares of company stock valued at $69,639,633. Insiders own 8.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Guggenheim increased their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Friday. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Thursday. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Citigroup upped their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $34.77.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.